Alzheimer disease trials in Argentina

In Argentina 17 Also abroad 815

17 trials · From ClinicalTrials.gov, checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)
Where
Buenos Aires, Córdoba, La Plata, Mar del Plata, Rosario
Age
55 years to 90 years
People
426 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT07011732 · EU 2025-520613-31-00
Phase 3Taking people
A Study of Trontinemab in Cognitively Unimpaired Individuals at Risk for Progression to Symptomatic Alzheimer's Disease
Where
Buenos Aires, Rosario
Age
55 years to 80 years
People
1,600 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT07717411
Phase 3Taking people
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease
Where
Buenos Aires, Ciudad Autonoma de Buenos Aires, Córdoba, Mendoza
Age
55 years to 90 years
People
426 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT07011745 · EU 2025-520612-34-00
Phase 3Taking people
A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
Where
Buenos Aires, Ciudad Autonoma de Buenos Aires, Ciudad Autónoma de Buenos Aires, Córdoba, Rosario
Age
55 years to 90 years
People
406 worldwide
Run by
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
See details and how to joinNCT06585787 · EU 2024-516363-92-00
Phase 3Taking people
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease
Where
Buenos Aires, Córdoba
Age
60 years to 85 years
People
586 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT06976216 · EU 2025-520746-30-00
Phase 2Taking people
A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)
Where
Caba, Ciudad de Buenos Aires
Age
50 years to 85 years
People
340 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT07033494 · EU 2024-519190-19-00
Phase 3Taking people
Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies
Where
Buenos Aires, C. A. B. A., Mendoza, Rosario, San Miguel de Tucumán
Age
50 years to 90 years
People
80,000 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT07177352
Phase 3Taking people
Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)
Where
Buenos Aires, Ciudad Autónoma de Buenos Aires, Córdoba, Rosario
Age
55 years to 90 years
People
1,000 worldwide
Run by
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
See details and how to joinNCT05980949 · EU 2023-504151-27-00
Phase 3Taking people
A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)
Where
Buenos Aires, Ciudad Autonoma de Buenos Aires, Córdoba, La Plata, Mar del Plata, Mendoza, Rosario
Age
55 years to 90 years
People
650 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT06937229 · EU 2024-519994-20-00
Phase 3Taking people
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)
Where
ABB, Buenos Aires, Córdoba, Mendoza
Age
60 years to 85 years
People
586 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT06976203 · EU 2025-520747-32-00
Phase 2Taking people
Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease
Where
Buenos Aires, Ciudad Autónoma de Buenos Aires, Córdoba, Mar del Plata, Mendoza, Santiago del Estero
Age
55 years to 90 years
People
120 worldwide
Run by
Celgene
See details and how to joinNCT06808984
No phaseTaking people
Dominantly Inherited Alzheimer Network (DIAN)
Where
Buenos Aires, Salta
Age
18 years and over
People
700 worldwide
Run by
Washington University School of Medicine
See details and how to joinNCT00869817
Phase 2Taking people
A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis
Where
Caba, Córdoba
Age
55 years to 90 years
People
300 worldwide
Run by
MapLight Therapeutics
See details and how to joinNCT06887192 · EU 2024-519820-26-00
Phase 2/3Taking people
A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
Where
Ciudad Autonoma de Buenos Aire
Age
18 years and over
People
280 worldwide
Run by
Washington University School of Medicine
See details and how to joinNCT05552157
Phase 2/3Taking people
A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
Where
Ciudad Autonoma de Buenos Aire
Age
18 years and over
People
280 worldwide
Run by
Washington University School of Medicine
See details and how to joinNCT06647498
No phaseTaking people
Memory for Music: Individual Intensive Musical Training in Alzheimer's Disease
Where
Buenos Aires
Age
65 years and over
People
113 worldwide
Run by
NORCE Norwegian Research Centre AS
See details and how to joinNCT06611878
Phase 2Taking people
Open-label Extension Study in Participants With Early Alzheimer's Disease
Where
Buenos Aires, Ciudad Autonoma de Bueno, Ciudad Autonoma de Buenos Aire
Age
50 years to 85 years
People
220 worldwide
Run by
GlaxoSmithKline
See details and how to joinNCT07105709